Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
NCT05636670 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180
Last updated 2022-12-05
Summary
Based on clinical manifestations, laboratory data and intestinal microflora detection, the cognitive function characteristics of patients with systemic lupus erythematosus and cerebrovascular disease and its relationship with intestinal microflora were analyzed to explore the possible pathogenesis of lupus cerebrovascular disease.
Conditions
- Lupus Erythematosus, Systemic
- Gastrointestinal Microbiome
Sponsors & Collaborators
-
Nanfang Hospital, Southern Medical University
lead OTHER
Principal Investigators
-
Qin Huang, MD · Southern Medical University
Eligibility
- Min Age
- 14 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-10-01
- Primary Completion
- 2023-09-30
- Completion
- 2024-09-30
Countries
- China
Study Locations
More Related Trials
-
Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus
NCT05880121 ·Status: RECRUITING
-
Different Aspects and Etiologies of Gastointestinal Bleeding in Patients With Systemic Lupus Erythematosus
NCT06641427 ·Status: NOT_YET_RECRUITING
-
The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity
NCT05689580 ·Status: UNKNOWN ·Phase: NA
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Accuracy, Feasibility and Acceptance of CGM Lupus
NCT03296995 ·Status: UNKNOWN ·Phase: NA
-
Metformin In Prevention of Lupus Nephritis
NCT04145687 ·Status: UNKNOWN ·Phase: PHASE4
-
Autoimmunity in Sisters of Lupus Patients
NCT01076101 ·Status: COMPLETED
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
NCT04276701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease
NCT02270710 ·Status: WITHDRAWN
-
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06676631 ·Status: RECRUITING ·Phase: PHASE1
-
A Pilot Study to Explore the Role of Gut Flora in Lupus
NCT04213690 ·Status: WITHDRAWN
-
Mast Cells Are Involved in the Mechanism of NPSLE Epilepsy
NCT05607368 ·Status: RECRUITING
-
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus
NCT02456168 ·Status: COMPLETED
-
Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
NCT01060410 ·Status: COMPLETED
-
Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients
NCT06610422 ·Status: NOT_YET_RECRUITING
-
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
NCT04440566 ·Status: COMPLETED ·Phase: NA
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
NCT04517240 ·Status: UNKNOWN
-
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
NCT02435368 ·Status: UNKNOWN
-
fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus
NCT06226324 ·Status: RECRUITING
-
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hematological Manifestations in Systemic Lupus Erythematosus Patients
NCT06936007 ·Status: COMPLETED
-
Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases
NCT06029335 ·Status: UNKNOWN